Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2563 | Nitric Oxide-Continuous and Sessions Wiki | 1.00 |
| drug2565 | Nitric Oxide-Sessions Wiki | 1.00 |
| drug3719 | Standard care Wiki | 0.33 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000860 | Hypoxia NIH | 0.20 |
| D011024 | Pneumonia, Viral NIH | 0.11 |
| D011014 | Pneumonia NIH | 0.05 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0012418 | Hypoxemia HPO | 0.20 |
| HP:0002090 | Pneumonia HPO | 0.05 |
Navigate: Correlations HPO
There is one clinical trial.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected the global population with significant morbidity and mortality. One of the main concerns is the management of the patients since there is no specific treatment for this condition. Therefore, in SARS-CoV-2 patients the compassionate use of off-label therapies has been initiated; such as the use of plasma from convalescent patients. This treatment has been used in other pandemics like SARS-CoV-1, H5N1, H1N1, Ebola, among others. This study is a phase II/III randomized clinical trial to assess the effectiveness and safety of convalescent plasma administration in patients with high-risk SARS-CoV-2.
Description: Death of the patient (yes/no)
Measure: Mortality Time: Up to 30 days after the study enrollmentDescription: Presence of any of the following adverse events (yes/no): Nonhemolytic febrile reactions Allergic reactions Acute hemolytic reactions Non-immune hemolysis Acute transfusion-related lung damage Transfusion-related circulatory overload Metabolic reactions Hypotensive reactions Delayed hemolytic reactions Post transfusion purple Graft versus host disease Bacterial contamination of blood components Viral infections Other infections (syphilis, prions, malaria, Chagas, yellow fever, dengue)
Measure: Adverse events Time: Up to 30 days after the study enrollmentDescription: Admitted to intensive care units (ICUs) (yes/no)
Measure: ICU admission Time: Up to 30 days after the study enrollmentDescription: Mechanical ventilation requirement (yes/no)
Measure: Mechanical ventilation Time: Up to 30 days after the study enrollmentDescription: Intensive care unit length of stay
Measure: ICU length Time: Up to 30 days after the study enrollmentDescription: D dimer reduction below 1mcg / ml
Measure: Reduction of D Dimer Time: Assessment at day 30 after study enrollmentDescription: Reduction of LDH below 350 IU / L
Measure: LDH reduction Time: Assessment at day 30 after study enrollmentDescription: Reduction of troponin level to than 8 pg / mL
Measure: Reduction of Troponin level Time: Assessment at day 30 after study enrollmentDescription: Decrease in ferritin level below 1025 mcg / L
Measure: Decrease in ferritin level Time: Assessment at day 30 after study enrollmentDescription: Decrease in procalcitonin level below 0.1ng / ml
Measure: Decrease in procalcitonin level Time: Assessment at day 30 after study enrollmentDescription: Decrease in CRP level bellow <8 mg / L
Measure: Decrease in CRP Time: Assessment at day 30 after study enrollmentDescription: Increase in lymphocyte count greater than 0.6 x 10-9 / L
Measure: Increase in lymphocyte count Time: Assessment at day 30 after study enrollmentDescription: Increase in PaO2 / Fio2 greater than 200
Measure: Increase in PaO2 / Fio2 Time: Assessment at day 30 after study enrollmentDescription: Scale of 24 points, greater number indicates worst outcome
Measure: Decrease in Sequential Organ failure assessment (SOFA ) score Time: Assessment at day 30 after study enrollmentDescription: Extracorporeal membrane oxygenation requirement (ECMO)
Measure: Extracorporeal membrane oxygenation (ECMO) Time: Assessment at day 30 after study enrollmentDescription: Decrease in the percentage of lung infiltration
Measure: Lung infiltration Time: Assessment at day 30 after study enrollmentAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports